The recent discovery of the type II prokaryotic CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system, originally discovered in the bacterium Streptococcus pyogenes that works as a mechanism to defend against viruses and foreign DNA, has provided a revolutionary tool for targeted genome engineering with simple elegance.
The system uses a nuclease, CRISPR-associated protein 9 (Cas9), that complexes with small guide RNAs (gRNAs) to cleave DNA in a sequence-specific manner upstream of the protospacer adjacent motif (PAM) in any genomic location.
BioCat offers a comprehensive portfolio for CRISPR/Cas9-based genome engineering including vector-based and Cas9 protein/gRNA-based systems, see below. For screening projects lentiviral gRNA libraries and Cas9 expressing cell lines are provided.
You need help to find the product of your interest? Please contact us!